158 related articles for article (PubMed ID: 11552898)
41. Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer.
Deva S; Jameson M
Cochrane Database Syst Rev; 2012 Aug; (8):CD007814. PubMed ID: 22895966
[TBL] [Abstract][Full Text] [Related]
42. ANTISECRETORY TREATMENT FOR PEDIATRIC GASTROESOPHAGEAL REFLUX DISEASE - A SYSTEMATIC REVIEW.
Mattos ÂZ; Marchese GM; Fonseca BB; Kupski C; Machado MB
Arq Gastroenterol; 2017 Dec; 54(4):271-280. PubMed ID: 28954042
[TBL] [Abstract][Full Text] [Related]
43. Indications for treatment of Helicobacter pylori infection: a systematic overview.
Veldhuyzen van Zanten SJ; Sherman PM
CMAJ; 1994 Jan; 150(2):189-98. PubMed ID: 8287341
[TBL] [Abstract][Full Text] [Related]
44. Serum pepsinogen can predict response to H2-receptor antagonist in patients with functional dyspepsia.
Yoshikawa I; Murata I; Kume K; Kanagawa K; Hirohata Y; Nakamura H; Otsuki M
Aliment Pharmacol Ther; 2002 Oct; 16(10):1805-9. PubMed ID: 12269975
[TBL] [Abstract][Full Text] [Related]
45. Treatment with cimetidine, antacid, or placebo in patients with dyspepsia of unknown origin.
Gotthard R; Bodemar G; Brodin U; Jönsson KA
Scand J Gastroenterol; 1988 Jan; 23(1):7-18. PubMed ID: 3278366
[TBL] [Abstract][Full Text] [Related]
46. Randomized clinical trial: rikkunshito in the treatment of functional dyspepsia--a multicenter, double-blind, randomized, placebo-controlled study.
Suzuki H; Matsuzaki J; Fukushima Y; Suzaki F; Kasugai K; Nishizawa T; Naito Y; Hayakawa T; Kamiya T; Andoh T; Yoshida H; Tokura Y; Nagata H; Kobayakawa M; Mori M; Kato K; Hosoda H; Takebayashi T; Miura S; Uemura N; Joh T; Hibi T; Tack J;
Neurogastroenterol Motil; 2014 Jul; 26(7):950-61. PubMed ID: 24766295
[TBL] [Abstract][Full Text] [Related]
47. Helicobacter pylori infection treatment of nonulcer dyspepsia: an analysis of meta-analyses.
Laheij RJ; van Rossum LG; Verbeek AL; Jansen JB
J Clin Gastroenterol; 2003 Apr; 36(4):315-20. PubMed ID: 12642737
[TBL] [Abstract][Full Text] [Related]
48. WITHDRAWN: Eradication of Helicobacter pylori for non-ulcer dyspepsia.
Moayyedi P; Soo S; Deeks JJ; Delaney B; Harris A; Innes M; Oakes R; Wilson S; Roalfe A; Bennett C; Forman D
Cochrane Database Syst Rev; 2011 Feb; (2):CD002096. PubMed ID: 21328254
[TBL] [Abstract][Full Text] [Related]
49. Eradication of Helicobacter pylori for non-ulcer dyspepsia.
Moayyedi P; Soo S; Deeks J; Delaney B; Harris A; Innes M; Oakes R; Wilson S; Roalfe A; Bennett C; Forman D
Cochrane Database Syst Rev; 2006 Apr; (2):CD002096. PubMed ID: 16625554
[TBL] [Abstract][Full Text] [Related]
50. Drug utilization evaluation of nonprescription H2-receptor antagonists and alginate-containing preparations for dyspepsia.
Krska J; John DN; Hansford D; Kennedy EJ
Br J Clin Pharmacol; 2000 Apr; 49(4):363-8. PubMed ID: 10759692
[TBL] [Abstract][Full Text] [Related]
51. [Therapy of duodenal ulcer with H2-blockers. 2 x 150 mg ranitidine versus 2 x 400 mg cimetidine].
Hüttemann W
Fortschr Med; 1983 Jan; 101(4):139-41. PubMed ID: 6131857
[TBL] [Abstract][Full Text] [Related]
52. Dyspepsia and reflux in primary care: rough DIAMOND of a trial.
van Zanten SV
Lancet; 2009 Jan; 373(9659):187-8. PubMed ID: 19150689
[No Abstract] [Full Text] [Related]
53. Policy analysis of the conversion of histamine2 antagonists to over-the-counter use.
Kalish SC; Bohn RL; Avorn J
Med Care; 1997 Jan; 35(1):32-48. PubMed ID: 8998201
[TBL] [Abstract][Full Text] [Related]
54. H2-blockers: how safe and how effective?
Spiro HM
J Clin Gastroenterol; 1983; 5 Suppl 1():143-7. PubMed ID: 6140282
[TBL] [Abstract][Full Text] [Related]
55. Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled trial.
van Marrewijk CJ; Mujakovic S; Fransen GA; Numans ME; de Wit NJ; Muris JW; van Oijen MG; Jansen JB; Grobbee DE; Knottnerus JA; Laheij RJ
Lancet; 2009 Jan; 373(9659):215-25. PubMed ID: 19150702
[TBL] [Abstract][Full Text] [Related]
56. Lack of efficacy of cisapride and nizatidine in dyspepsia.
Adelman A; Alper BS
J Fam Pract; 1998 Jun; 46(6):457-8. PubMed ID: 9638107
[No Abstract] [Full Text] [Related]
57. Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome.
Howard JM; Chremos AN; Collen MJ; McArthur KE; Cherner JA; Maton PN; Ciarleglio CA; Cornelius MJ; Gardner JD; Jensen RT
Gastroenterology; 1985 Apr; 88(4):1026-33. PubMed ID: 2857672
[TBL] [Abstract][Full Text] [Related]
58. Eradication of Helicobacter pylori for non-ulcer dyspepsia.
Moayyedi P; Soo S; Deeks J; Delaney B; Harris A; Innes M; Oakes R; Wilson S; Roalfe A; Bennett C; Forman D
Cochrane Database Syst Rev; 2003; (1):CD002096. PubMed ID: 12535429
[TBL] [Abstract][Full Text] [Related]
59. Eradication of Helicobacter pylori for non-ulcer dyspepsia.
Moayyedi P; Soo S; Deeks J; Delaney B; Harris A; Innes M; Oakes R; Wilson S; Roalfe A; Bennett C; Forman D
Cochrane Database Syst Rev; 2001; (1):CD002096. PubMed ID: 11279751
[TBL] [Abstract][Full Text] [Related]
60. Eradication of Helicobacter pylori for non-ulcer dyspepsia.
Moayyedi P; Soo S; Deeks J; Delaney B; Harris A; Innes M; Oakes R; Wilson S; Roalfe A; Bennett C; Forman D
Cochrane Database Syst Rev; 2005 Jan; (1):CD002096. PubMed ID: 15674892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
